Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing references an earnings press release, but the provided text contains no operating or financial results.
Arcturus Therapeutics Holdings Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing references an earnings press release, but the provided text contains no operating or financial results
- Investor focus: pipeline execution for ARCT-032 and ARCT-810, including Phase 2 enrollment and potential Phase 3 timing
- Management highlights cash position, expected cash burn and runway as forward-looking considerations
- Forward-looking statements subject to clinical, regulatory, funding and commercialization risks
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $3.0M versus $28.3M, reflecting sharply reduced CSL Seqirus collaboration revenue ahead of termination
- Net loss widened to $23.8M, or $0.84 per share, versus $9.2M, or $0.34, despite lower R&D spending
- Cash fell to $191.5M from $230.9M at year-end; management projects runway through year-end 2028
- CSL settlement returns global KOSTAIVE® and infectious-disease rights, plus $12M cash and approximately $16M released liabilities
- ARCT-032 Phase 2 enrollment remains on schedule, with Phase 3 decision expected in Q4 2026; ARCT-810 dosing completed ahead of Q3 updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcturus Therapeutics Holdings Inc. 8-K filings
Get the next ARCT 8-K as it lands
Follow ARCT for push alerts, or ask the research agent what this filing means.